What the FDA labels say about taking them together
Morphine and prasugrel
Morphine's FDA label (Morphine Sulfate) of August 31, 2026 names prasugrel in its drug interactions section, and prasugrel's label names morphine too. The morphine label: “The co-administration of oral P2Y 12 inhibitors and intravenous morphine sulfate can decrease the absorption and peak concentration of oral P2Y 12 inhibitors and delay the onset of antiplatelet effect.”
Check it at the source: the morphine FDA label on DailyMed (effective July 13, 2026, Bryant Ranch Prepack); the prasugrel FDA label on DailyMed (effective February 11, 2025, Panacea Biotec Limited).
What does the morphine label say about prasugrel?
Morphine Sulfate label (Fresenius Kabi, USA LLC, August 31, 2026), drug interactionsOral P2Y 12 Inhibitors Clinical Impact: The co-administration of oral P2Y 12 inhibitors and intravenous morphine sulfate can decrease the absorption and peak concentration of oral P2Y 12 inhibitors and delay the onset of antiplatelet effect. Intervention: Consider the use of a parenteral antiplatelet agent in the setting of acute coronary syndrome requiring co-administration of intravenous morphine sulfate. Examples: clopidogrel, prasugrel, ticagrelor
Source: FDA drug label (Morphine Sulfate, NDA204223), Fresenius Kabi, USA LLC, effective August 31, 2026 (SPL set 1f53de80-efc8-4930-b3e3-fba0d026af05), via openFDA
Source: FDA drug label (Morphine sulfate), ANDA078761 (Sun Pharm Inds Ltd), as published by Bryant Ranch Prepack, effective July 13, 2026 (SPL set 595243fe-a4b1-479a-99d6-a084a4181891), via openFDA; the full label on DailyMed
What does the prasugrel label say about morphine?
Prasugrel label, drug interactionsConsider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists
Source: FDA drug label (Effient, NDA022307), Cosette Pharmaceuticals, Inc., effective September 7, 2022 (SPL set 69ea2d58-5353-4222-b61f-cab976fa7e5e), via openFDA
Source: FDA drug label (PRASUGREL), Panacea Biotec Limited, effective February 11, 2025 (SPL set 944c195a-de24-a44c-8baa-84b624b5ddcb), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Morphine | Prasugrel | |
|---|---|---|
| Labeled for | Pain | Heart attack and coronary artery disease, Angina |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.226 per tablet 15 mg tablet | $0.263 per tablet 10 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once